Rubric Capital and Velan Capital Reach Agreement with Heron Therapeutics for Board Representation and Corporate Governance Improvements

Firm News

MarketWatch, Insightia (subscription required) and other media sources reported on the agreement Olshan clients Rubric Capital and Velan Capital reached with Heron Therapeutics pursuant to which three new independent directors were appointed to Heron’s board – including Adam Morgan of Velan Capital – and two incumbent directors departed the board. The company also agreed to separate the Chairman and CEO roles effective immediately following the company’s upcoming annual meeting. Vice Chair of Olshan’s Shareholder Activism practice Ryan Nebel represented Rubric Capital and Velan Capital in connection with their agreement with Heron Therapeutics.

Media Contact

Marketing Contact
Mizi Mehaj
Marketing & Administrative Manager

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.